Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 1996. The state of the art may have changed since the publication date.
Reuters NewMedia, Inc. - 10 July 1996
Glaxo's AIDS drugs, Epivir and Retrovir, have been brought to the forefront this week as an international AIDS conference takes place in Vancouver, Canada.
"A new and exciting story is emerging...that could see (Glaxo-Wellcome) group sales in the HIV area increase more than fivefold over the coming years," BZW pharmaceutical analyst Steve Plag wrote in a research note issued this week.
Glaxo shares closed 12 pence higher at 891 pence, having hit 897 pence earlier in the day.
The new AIDS therapy that is being reviewed by doctors, researchers, pharmaceutical companies and others in Vancouver, combines three drugs, two of which are sold by Glaxo Wellcome.
Worldwide sales of Retrovir, known as AZT, were 201 million pounds ($311.6 million) in 1995. Glaxo's total sales in 1995 hit 10.5 billion pounds.
Sales in the United States, the only country to approve Epivir, were 12 million pounds in the last half of 1995.
Plag said Epivir's initial sales had been "...nothing short of stunning."
Glaxo Wellcome's other AIDS drugs include 3TC (which is licensed by it from Biochem Pharma Inc) and 1592. ($1-.6451 Pound)
960710
RE960775
Copyright © 1996 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1996. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .